This review discusses metronomic chemotherapy's impact on tumor growth in elderly patients, highlighting its benefits and improved patient compliance.
In China, elderly individuals (≥60 years) face a growing cancer burden, accounting for 55.8% of new cases and 68.2% of deaths. Metronomic chemotherapy offers a promising approach by using continuous low-dose treatment to inhibit tumor growth with fewer side effects. breaking through the cycle-dependent limitations of traditional chemotherapy, this review discusses its applications and benefits for elderly cancer patients, aiming to support clinical practice, at the same time, significantly improves patient compliance and the quality of life of elderly patients.
No takes yet. Share an insight, caveat, or question.
Yizhu Wang (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: